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Background: Granulomatosis with polyangiitis (GPA, Wegener’s) and microscopic polyangiitis (MPA) are small
vessel vasculitides collectively referred to as anti-neutrophil cytoplasm antibody-associated vasculitis (AAV). AAV is
associated with high rates of morbidity and mortality due to uncontrolled disease and treatment toxicity. Small
randomized trials suggest adjunctive plasma exchange may improve disease control, while observational evidence
suggests that current oral glucocorticoid doses are associated with severe infections in patients with AAV. A
randomized study of both plasma exchange and glucocorticoids is required to evaluate plasma exchange and oral
glucocorticoid dosing in patients with AAV.
Methods/design: PEXIVAS is a two-by-two factorial randomized trial evaluating adjunctive plasma exchange and
two oral glucocorticoid regimens in severe AAV. Five hundred patients are being randomized at centers across
Europe, North America, Asia, and Australasia to receive plasma exchange or no plasma exchange, and to receive
standard or reduced oral glucocorticoid dosing. All patients receive immunosuppression with either
cyclophosphamide or rituximab. The primary outcome is the time to the composite of all-cause mortality and end-
stage renal disease.
PEXIVAS is funded by the National Institute of Health Research (UK), the Food and Drug Administration (USA), the
National Institutes of Health (USA), the Canadian Institute of Health Research (Canada), the National Health and
Medical Research Council (Australia), and Assistance Publique (France). Additional in-kind supplies for plasma
exchange are provided by industry partners (TerumoBCT, Gambro Australia, and Fresenius Australia).
Discussion: This is the largest trial in AAV undertaken to date. PEXIVAS will inform the future standard of care for
patients with severe AAV. The cooperation between investigators, funding agencies, and industry provides a model
for conducting studies in rare diseases.
Trial registration: Current Controlled Trials: (ISRCTN07757494) and clinicaltrials.gov: (NCT00987389)
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Granulomatosis with polyangiitis (GPA, Wegener’s) and
microscopic polyangiitis (MPA) are syndromes of pri-
mary systemic vasculitis associated with anti-neutrophil
cytoplasm antibodies (ANCA). Together, these syn-
dromes are grouped as ANCA-associated systemic vas-
culitis (AAV). The prevalence of AAV is 14 to 30
patients per 100,000 [1]. The most common severe AAV
manifestations are glomerulonephritis, leading to renal
failure and alveolar capillaritis causing lung hemorrhage.
The current standards of care for initial treatment are
either combination cyclophosphamide (CYC) and glu-
cocorticoid (GC) therapy or rituximab and GC therapy.
Although these treatments have significantly improved
survival compared to untreated AAV, overall survival is
still poor and many patients suffer from chronic morbi-
dity including end-stage renal disease (ESRD) [2,3].
Poor survival and ESRD in AAV are attributed both to
ineffective therapies and treatment toxicity [2]. At least
20% of patients do not achieve disease control or are in-
tolerant of initial treatment, and an additional 50% will
relapse by 5 years [4,5]. Inadequate disease control re-
sults in increased immunosuppressive exposure and risk
of treatment-related toxicity, progressive organ scarring,
and ultimately death [6]. CYC and GC are also associ-
ated with high rates of early mortality due to infection
[7]. Between 25% and 50% of patients with severe AAV
experience a severe infection within the first 12 months
of treatment and the most frequently cited causes of
death are infection or uncontrolled vasculitis [8,9].
Strategies that improve disease control and reduce
toxicity early in treatment will likely have the largest
impact on survival, rates of ESRD, and subsequent
disease course. PEXIVAS will evaluate two therapies,
one to improve early disease control and one to limit
early toxicity.
Plasma exchange (PLEX) was introduced into the
treatment of pauci-immune glomerulonephritis follo-
wing its efficacy in the related anti-glomerular basement
membrane (GBM) disease, a disease with renal and pul-
monary vasculitis induced by pathogenic anti-GBM anti-
bodies [10]. The subsequent discovery of ANCA, their
close association with GPA and MPA, and animal
models supporting the concept of ANCA as pathogenic
antibodies, has provided a rationale for PLEX in AAV.
Additional potential beneficial effects of PLEX in AAV
include removal of other mediators of inflammation and
coagulation, and effects on immunoregulation. Further-
more, small trials comparing PLEX to standard treatments
suggest benefits for patients with kidney involvement at
presentation [11-13]. Observational work also suggests
those with highly active AAV are more likely to benefit
from PLEX than those with more chronic presentations
[14,15].Lung hemorrhage is among the most common
vasculitis-related causes of early death in AAV and PLEX
is widely used for this presentation. This practice comes
from cohort data in AAV and extrapolated experience
with anti-GBM disease [16-18]. However, PLEX has the
potential to exacerbate hemorrhage through removal of
clotting factors and increases the risk of infection through
antibody removal. Furthermore, the observational data
most commonly cited focus on non-contemporaneous pa-
tients often with severe manifestations of lung hemor-
rhage [16]. Contemporary patients are usually diagnosed
earlier in their disease course due to the availability of
ANCA testing, heightened awareness of the disease, and
more routine use of CT scanning, bronchoscopy, and
broncho-alveolar lavage.
PLEX is invasive, expensive, labor intensive, and asso-
ciated with adverse events. There is insufficient high-
quality evidence supporting the use of PLEX in AAV,
although there are promising data suggesting PLEX may
improve survival and prevent ESRD in AAV [8,12]; if
this is true, PLEX may be a valuable and cost-effective
treatment. Due to the uncertainties surrounding the use
of PLEX in AAV, there is a need for a randomized con-
trolled trial examining the effect of PLEX on the impor-
tant clinical outcomes of ESRD and all-cause mortality.
Oral GC are used ubiquitously in the early manage-
ment of AAV. There is a complex relationship between
GC dose and its effects on the immune system as an
immunosuppressive versus an anti-inflammatory agent
[19]. When combined with cytotoxic medications, high-
dose GC may significantly increase treatment-related
toxicity while adding little to therapeutic efficacy. Labo-
ratory data suggest lower GC doses may mitigate their
toxicity while maintaining anti-inflammatory effects [20].
However, there is often a reluctance to reduce GC doses
due to their perceived efficacy at higher doses and the
association of the disease with poor outcomes when it is
not adequately controlled.
Infections in AAV are most common in the first 6
months of treatment when GC doses are highest [8]. Al-
though this relationship is confounded by disease activ-
ity and co-treatment with CYC, it is important to note
that infection rates fall in parallel with decreasing GC
dose despite the maintenance of constant immunosup-
pression over time. Replacement of CYC by rituximab
has not reduced early infection rates in severe AAV, a
finding that supports a major role of GC in infective risk
[9,21]. The concept that higher doses of GC increase
toxicity without improving treatment efficacy in im-
munologic diseases is supported from evidence in
rheumatoid arthritis and lupus nephritis where a dose-
dependent increase in infections is observed with increa-
sing GC dose [22-24]. Furthermore, high cumulative
doses of GC are associated with osteoporosis, infections,
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[22]. In renal transplantation, concern over GC toxicity
prompted early GC withdrawal and even GC avoidance
regimens. Meta-analyses of these trials have shown that
protocols utilizing more rapid GC withdrawal have not
lead to increases in ESRD or death [25,26]. Despite the
association between higher GC doses and adverse events
and despite their widespread use, there is a paucity of li-
terature to guide the optimal use of GC in AAV.
AAV is a rare disease that has ‘orphan’ status in both
the US and EU. There are extensive challenges to con-
ducting large, randomized, controlled trials in rare dis-
eases including the need for a large number of study
sites to achieve recruitment goals, usually many years
for the recruitment period, higher costs per patient com-
pared to studies of common diseases, relative disinterest
on the part of the biomedical industry to address clinical
problems with small market potential, few drugs with
existing indications for a rare disease, and skepticism by
funding agencies of the feasibility of such studies [27].
Conducting adequately powered trials in rare diseases
requires establishment of research alliances and ‘buy-in’
by a large number of investigators. Collaborative networks
of vasculitis investigators have developed in Europe and
North America and have established a track record in
completing clinical trials and methodologies for their
conduct.
There is a need for therapies for AAV with both reduced
toxicity and improved disease control. Defining the role of
therapies that are already in use but unproven is a priority
for research in AAV. PEXIVAS is a randomized clinical
trial testing two interventions in a two-by-two factorial de-
sign (standard care and PLEX compared to standard care
alone and a standard dose GC compared to a reduced
dose GC regimen) to address these issues (ISRCTN #
ISRCTN07757494; NCT #NCT00987389).
Methods/design
PEXIVAS is an international, open-label, two-by-two fac-
torial design, randomized controlled trial examining: (1)
the effect of adjunctive PLEX on the composite end-
point of death/ESRD; and (2) the effect of reduced com-
pared to standard glucocorticoids, during the first 6
months, on death/ESRD. Eligible patients are allocated
to one of four regimens: (1) PLEX and standard dose
GC; (2) PLEX and reduced dose GC; (3) no PLEX and
standard dose GC; and (4) no PLEX and reduced dose
GC (Figure 1).
Allocation will be performed using an online web-based
system developed by the data coordinating center
(Birmingham Clinical Trials Unit, UK) using minimi-
zation. The minimization algorithm is not fully determin-
istic (that is, the probability of allocation to particular
group will never be 1. Minimization strata are based onthe following factors: severity of renal disease at presen-
tation (requiring dialysis or creatinine ≥500 μmol/L vs.
<500 μmol/L), age (<60 vs. ≥60 years old), ANCA subtype
(PR3-ANCA vs. MPO-ANCA), severity of lung hemor-
rhage (no hemorrhage, lung hemorrhage with an oxygen
saturation of ≤85% on room air or ventilated, or lung
hemorrhage with an oxygen saturation of >85% on room
air), and type of induction therapy (oral CYC vs. intrave-
nous (IV) CYC vs. rituximab).
Participants
Eligible patients have a diagnosis of active AAV that is
consistent with the Chapel-Hill consensus definitions of
GPA, MPA or renal limited vasculitis, a positive ANCA
to the proteinase 3 or myeloperoxidase serotypes, and a
severe manifestation of AAV. A severe manifestation is
defined as either renal involvement with a documented
estimated glomerular filtration rate <50 mL/min, in
addition to hematuria and proteinuria or a renal biopsy
demonstrating focal necrotizing glomerulonephritis. Al-
ternatively, patients with lung hemorrhage defined as
radiographic evidence in the absence of an alternative
explanation in addition to at least one of the following:
evidence from broncho-alveolar lavage, frank hemop-
tysis, an elevation in the diffusing capacity of carbon
monoxide, or an otherwise unexplained drop in hemo-
globin of at least 2 g/dL.
Patients are excluded if they have concomitant anti-
GBM disease, a type of vasculitis other than AAV, are
pregnant, required dialysis for at least 21 days prior to
randomization, have a renal transplant, have received
PLEX within the prior 3 months, have significant CYC
exposure, rituximab, or high dose GC prior to rando-
mization, or in the opinion of the treating physician have
an absolute indication or contraindication to PLEX or a
particular GC regimen or an absolute contraindication
to both CYC and rituximab.
Informed consent is obtained from the participant. At
centers where surrogate consent is ethically approved,
informed consent for participants who lack capacity may
be obtained from a surrogate decision-maker.
Interventions
Plasma exchange
PLEX is adjunctive to standard induction therapy and
consists of seven exchanges over 14 days of 60 mL/kg per
session using 3% to 5% albumin as a replacement solution.
Fresh frozen plasma may be used to replace clotting fac-
tors in patients at risk of hemorrhage, for example, after
renal biopsy or with pulmonary hemorrhage. Other com-
ponents of the PLEX prescription are determined by local
investigator experience and feasibility, including: PLEX
modality (centrifugation or filtration), type of anticoa-
gulation, daily or alternate day frequency and route of
Severe AAV















Figure 1 General schema of treatment allocation.
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double membrane filtration) apheresis or immunoabsorp-
tion are not permitted.
Glucocorticoids
Investigator consensus determined the standard dose regi-
men of GC (Table 1). The reduced dose regimen provides
approximately 55% of the standard dose regimen over the
first 6 months. Both regimens are preceded by IV methyl-
prednisolone of between 1 and 3 grams. Oral GC may be
provided as prednisolone or prednisone according to local
practice.Table 1 Glucocorticoid dosing in the standard and
reduced-dose groups of PEXIVAS
Week Standard Reduced-dose
<50 kg 50-75 kg >75 kg <50 kg 50-75 kg >75 kg
Pulse Pulse Pulse Pulse Pulse Pulse
1 50 60 75 50 60 75
2 50 60 75 25 30 40
3-4 40 50 60 20 25 30
5-6 30 40 50 15 20 25
7-8 25 30 40 12.5 15 20
9-10 20 25 30 10 12.5 15
11-12 15 20 25 7.5 10 12.5
13-14 12.5 15 20 6 7.5 10
15-16 10 10 15 5 5 7.5
17-18 10 10 15 5 5 7.5
19-20 7.5 7.5 10 5 5 5
21-22 7.5 7.5 7.5 5 5 5
23-52 5 5 5 5 5 5
>52 Investigators’ Local Practice Investigators’ Local PracticeOther treatments
Patients are treated with either oral or IV CYC, or ritu-
ximab, as induction immunosuppression according to
local practice, patient needs, and physician preference.
CYC doses are reduced for advanced age and reduced
renal function. Infection and osteoporosis prophylaxis,
and blood pressure management are left to the discre-
tion of the local investigator.
Outcomes
The primary outcome is the time to the composite of
death from any cause and ESRD. ESRD is defined as the
requirement for at least 12 consecutive weeks of renal
replacement therapy (hemodialysis, peritoneal dialysis,
and/or continuous renal replacement therapy) or renal
transplantation.
Secondary outcomes include death from any cause
and ESRD separately, health-related quality of life as
measured by the Physical Component and Mental Com-
ponent Scores of the Short-Form 36 and EuroQoL
EQ-5D index score, serious infections, number of ser-
ious adverse events, and proportion with a sustained
remission. A sustained remission is defined as the
achievement of remission prior to 26 weeks and lasting
until at least week 52.
Blinding
This is an open label trial. Blinding of both patients and
investigators to PLEX by using a sham PLEX procedure
was not considered feasible for this trial. Due to the com-
plexity of the GC regimen it was not feasible logistically or
financially to blind the glucocorticoid intervention. To
minimize the potential for treatment contamination, the
use of non-randomized PLEX for severe, refractory disease
must be discussed with the study medical monitor and
investigators are provided active feedback on adherence to
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Similarly, co-interventions in AAV are limited as patients
are uniformly treated for the first year, and subsequent co-
interventions are unlikely to influence the trial outcomes.
Further, the trial outcomes are unambiguous and objective
so the lack of blinding is unlikely to create biased outcome
reporting.
Assessments
Participants are identified by referral at each study cen-
ter. Recruited participants are seen frequently during the
first 3 months of the trial (baseline, 2 weeks, 4 weeks,
8 weeks, and 12 weeks) to ensure adherence to the allo-
cated treatments and because adverse events and mor-
tality in the first 3 months are higher than subsequent
time periods. Participants are then seen every 3 months
to the end of the first year and then every 6 months to
the end of the trial.
Sample size
The sample size estimate for this trial assumes a 6-year
median time to ESRD or death on the basis of previous
extended follow-up studies in randomized trials of AAV
of a similar severity to those targeted in this study
(Figure 2). Enrollment is estimated to take 5 years with a
common close out after the last patient has been fol-
lowed for 2 years, hence a maximum follow-up of 7
years. Using time-to-event analysis and allowing a 10%
loss to follow-up in both groups, 490 patients are re-
quired to detect a hazard ratio of 0.64 with 80% power
and a two-sided alpha of 0.05. We intend to enroll 500
patients. This predicts approximately 164 events over
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Figure 2 Differences in long-term renal survival (end-stage
renal disease or death) on the basis of estimated glomerular
filtration (eGFR) for patients with ANCA-associated vasculitis
enrolled in three randomized trials. Blue line represents patients
with an eGFR of ≤ 50 mL/min/1.73 m2; red line represents patients
with an eGFR of >50 mL/min/1.73 m2.reduction of the primary end-point at 5 years (44% in
the control group vs. 32% in PLEX group). These calcu-
lations assume no significant interaction between the
two treatment factors. Although this absolute risk ap-
pears larger than is often clinically significant, the expen-
sive and invasive nature of PLEX warrants a relatively
large effect size.
While this effect size appears reasonable to detect a
moderately large effect for PLEX, it is unlikely a reduc-
tion in GC will result in a 12% absolute risk reduction of
death or dialysis. However, we expect approximately 25%
of patients to experience a severe infection based on
prior studies. A sample size of 500 patients will allow
80% power to detect at least a 10% absolute risk reduc-
tion in severe infections (relative risk reduction of severe
infection by 40%), a finding of clinical significance. In
terms of the non-inferiority hypothesis, a sample size of
500 patients would allow 80% power to ensure that the
reduced dose GC regimen results an increase in ESRD
or death by no more than 11% (one-sided alpha of 0.05).
However, given dose changes are permitted in response
to the clinical events that likely mediate the effects of
GC on death and ESRD (that is, uncontrolled disease
and infections), it is unlikely that one regimen is sub-
stantially inferior to the other in terms of the composite
end-point.
Data management
Data collection is facilitated by either paper-based case
report forms or secure electronic case report forms
completed online. Research coordinators and/or investi-
gators at each site complete the case report forms, and
check them for accuracy and completeness by reviewing
source documents and through regular interaction with
the participants clinical care providers. Any queries arising
from missing data or data anomalies will be resolved.
Data monitoring committee (DMC)/data safety and
monitoring board (DSMB)
The DMC/DSMB is composed of three members: an ex-
pert in vasculitis, a statistician, and an expert in clinical
trials (chair). Either trial intervention may be disconti-
nued in the event of clear evidence of harm or benefit.
The Haybittle-Peto approach of 3 standard errors will be
used as a guideline for a recommendation to stop early
at an interim analysis.
Analyses
All primary analyses will evaluate all patients according
to their allocated treatment group. Since a true, qualita-
tive interaction is unlikely we will assume there is no
interaction between PLEX and GC regimen unless there
is substantial evidence and rationale for the contrary at
the time the primary analyses are undertaken. As such,
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vs. no PLEX will be evaluated independently from, but
stratified by, standard vs. reduced dose glucocorticoid
regimen and vice versa). Point estimates and their corre-
sponding 95% confidence intervals and p values will be
calculated for all estimates of effect. A p value of <0.05
will be considered statistically significant without adjust-
ment for multiple testing.
The time to the composite end-point of death and
ESRD as well as death and ESRD individually will be an-
alyzed by time-to-event methods. We will also assess the
proportion of the patients that experience the composite
outcome by the end of the first year.
We will also perform analyses according to the following
subgroups: severity of renal disease at presentation (requir-
ing dialysis or creatinine ≥500 μmol/L vs. <500 μmol/L);
age (<60 vs. ≥60 years old); ANCA binding specificity (PR3
vs. MPO); severity of lung hemorrhage (no hemorrhage,
hemorrhage with blood oxygen saturation >85% on room
air, or hemorrhage with blood oxygen saturation ≤85% on
room air); induction immunosuppression therapy used (IV
CYC vs. oral CYC vs. rituximab. Additionally, due to the
potential that the investigational treatments may largely
affect early mortality and renal function, analyses of the
primary outcome (the composite of death and ESRD) will
also be performed after censoring data at 12-month
follow-up.
Discussion
PEXIVAS will provide important insights on two treat-
ment strategies for patients with severe AAV. PEXIVAS
is also noteworthy in several respects. Considering AAV
is a rare disease, PEXIVAS is a relatively large trial and
is the largest trial conducted or planned in AAV, or any
form of vasculitis, to date. As such, it plans to recruit
from between 60 and 90 centers worldwide and has ca-
pitalized on existing networks including the European
Vasculitis Study Group, the Vasculitis Clinics Research
Consortium, and the Australasian Kidney Trials Net-
work. Enhanced network development will have benefits
beyond PEXIVAS, including biomarker development and
the conduct of further randomized trials in vasculitis.
Given the scope of this undertaking, a two-by-two fac-
torial design enhances the efficiency of evaluating im-
portant therapies for this disease.
PEXIVAS will investigate two old, well-known therap-
ies for which there is substantial practice pattern vari-
ation. Further, one of these therapies is expensive and
invasive in that it requires an extracorporeal circuit and
represents an additional therapy to improve the efficacy
of early treatment (PLEX) while the other is inexpensive,
and is a de-escalation of therapy to reduce toxic side ef-
fects of early treatment (reduced dose regimen of gluco-
corticoids). PEXIVAS is also the first trial to activelyseek and randomize patients with lung hemorrhage, a
manifestation of AAV that is understudied and for which
there is no high quality evidence to guide treatment.
Trial status
PEXIVAS first received ethical approval from the Outer
West London Research Ethics Committee of the UK
National Research Ethics Service on November 5, 2009
(reference number 09/H0709/56). As of February 22,
2013 PEXIVAS is actively recruiting in 67 centers with
additional centers planned. A total of 219 of the planned




AAV: Anti-neutrophil cytoplasm antibody associated vasculitis; ANCA: Anti-
neutrophil cytoplasm antibody associated vasculitis; CYC: Cyclophosphamide;
DMC: Data monitoring committee; DSMB: Data safety monitoring board;
ESRD: End-stage renal disease; GBM: Glomerular basement membrane;
GC: Glucocorticoids; GPA: Granulomatosis with polyangiitis; IV: Intravenous;
MPA: Microscopic polyangiitis; MPO: Myeloperoxidase; PLEX: Plasma
exchange; PR3: Proteinase 3.
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